Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
New discoveries about the immune defenses of rare HIV patients who produce antibodies that prevent infection suggest a novel direction for designing new vaccines.
Researchers at Rockefeller University and colleagues have now made two fundamental discoveries about the so-called broadly neutralizing anti-HIV antibodies, which effectively keep the virus at bay. By detailing the molecular workings of a proven immune response, the researchers hope their work will ultimately enable them to similarly arm those who are not equipped with this exceptional immunological firepower. The findings are reported in the September 30 issue of the journal Nature.
"Nobody yet can make a vaccine that elicits these broadly neutralizing antibodies, but here are patients who can do it, so let's understand how," says Michel C. Nussenzweig, Sherman Fairchild Professor and head of the Laboratory of Molecular Immunology. "That's the theme in this work. The reason the research community is not making this vaccine is not that we're not good engineers. We are. The reason is that we don't understand how these patients produce these antibodies, and that's what we're figuring out. If we know how they're doing it, we might learn how to reproduce it."
HIV strains mutate rapidly, making them notoriously evasive targets for the immune system. In particular, the HIV envelope spike, called gp160, is the site of a host of mutations that obstruct the few elements that all of the virus strains share. Prior research has shown that only four superantibodies block the activity of that protein in a broad range of HIV strains, neutralizing the virus. But all attempts to coax the human body into producing those four have failed.
Last year, in experiments reported in Nature, the Nussenzweig lab showed that a diverse group of broadly neutralizing antibodies cloned from 433 B cells of six slow progressing HIV patients were as capable of knocking down a broad range of HIV strains as any one of the superantibodies. The ability to isolate and clone antibodies from B cells was first worked out by the lab in a pioneering 2003 paper in Science. Now, having applied that method to the B cells in HIV patients with high titers of broadly neutralizing antibodies, the new research explores in more detail what their antibodies target and how they attack.
In work to be published September 30 in Nature, postdoc Hugo Mouquet, Nussenzweig, and colleagues found a surprising result. Most antibodies are traditionally thought to bind to their target, or antigen, in a bivalent fashion, meaning they get a firm grip by taking hold of two specific handles. But HIV virions do not allow for that possibility because the gp160 spikes are too far apart. Therefore, antibodies to the virus are handicapped because they can only use one of their two high affinity arms to recognize the viral spike.
The researchers found that on average 75% of the anti-gp160-HIV antibodies in their large collection were selected by the immune system for polyreactivity, a property that allowed the second "free" arm of the antibody to enhance overall affinity by binding to the virion "nonspecifically." Generally, the immune system weeds out polyreactive antibodies, even though they are naturally produced in significant quantities, because polyreactive antibodies could in theory attack the body itself.
But the experiments suggest that these "sticky" antibodies may be an opportunistic adaptation to difficult cases such as HIV, in which homotypic bivalent bonding may not be an option. This particular cadre of polyreactive antibodies takes a long time -- years -- to develop in slow progressing HIV patients, and much remains to be discovered about that process, but the researchers believe that vaccine designed to elicit antibodies that mimic these properties could be a promising strategy to beat the deadly virus.
In related research published in August in The Journal of Experimental Medicine, visiting student John Pietzsch, Nussenzweig, and colleagues mapped the target of the largest single group of neutralizing antibodies found in HIV-infected patients with broadly neutralizing serologic activity. These antibodies including one of the recently described super antibodies, targeted a previously undefined region of the HIV envelope protein, a region that is nearby but distinct from the site targeted by previously described super antibodies. By mutating individual amino acids of this target and discovering that the result was an impotent virus, they showed that the largest group of broadly neutralizing antibodies targets a region on the HIV envelope spike that is indispensable for infection.
"The largest group of the HIV neutralizing antibodies was unmapped -- this group might have been specific for a number of different sites on the virion," Nussenzweig says. "But they are directed to a single core epitope on the viral spike, near the CD4 binding site. Our findings extend the footprint of what a neutralizing antibody can see."
This site, a core element of the HIV envelope spike that is shared by a full range of HIV strains, is an attractive new target that should be considered for vaccine design, the scientists say, and they are working on how to attack it. Nussenzweig, whose lab has only in the last couple of years begun working on HIV antibodies, says, "We're making basic discoveries about how antibodies work by studying a disease in patients. We could not do this work in a model organism."
From our Sponsors
Most Popular
Why activist Raif Derrazi thinks his HIV diagnosis is a gift
September 17 2024 12:00 PM
Out100 Honoree Tony Valenzuela thanks queer and trans communities for support in his HIV journey
September 18 2024 12:00 PM
How fitness coach Tyriek Taylor reclaims his power from HIV with self-commitment
September 19 2024 12:00 PM
Creator and host Karl Schmid fights HIV stigma with knowledge
September 12 2024 12:03 PM
Ricky Martin delivers showstopping performance for 2024 World AIDS Day
December 05 2024 12:08 PM
California confirms first case of even more deadly mpox strain
November 18 2024 3:02 PM
Eureka is taking a break from competing on 'Drag Race' following 'CVTW' elimination
August 20 2024 12:21 PM
Plus: Featured Video
Latest Stories
Celebrating Black History Month with our annual African American issue
February 01 2025 3:28 PM
Trump's orders prompt CDC to erase HIV resources
January 31 2025 5:29 PM
SFAF's Dr. Tyler TerMeer says he'll continue to fight for health care for all
January 28 2025 3:00 PM
Lexi Love goes public with HIV status after Trump wipes resources from federal website
January 23 2025 11:23 AM
Plus nominated for 2025 GLAAD Media Award alongside industry giants like Vogue, People, and Variety
January 22 2025 12:42 PM
A camp for HIV-positive kids is for sale. Here's why its founder is celebrating
January 02 2025 12:21 PM
This long-term HIV survivor says testosterone therapy helped save his life.
December 16 2024 8:00 PM
'RuPaul's Drag Race' star Trinity K Bonet quietly comes out trans
December 15 2024 6:27 PM
AIDS Memorial Quilt displayed at White House for the first time
December 02 2024 1:21 PM
Decades of progress, uniting to fight HIV/AIDS
December 01 2024 12:30 PM
Hollywood must do better on HIV representation
December 01 2024 9:00 AM
Climate change is disrupting access to HIV treatment
November 25 2024 11:05 AM
Post-election blues? Some advice from mental health experts
November 08 2024 12:36 PM
Check out our 2024 year-end issue!
October 28 2024 2:08 PM
Meet our Health Hero of the Year, Armonté Butler
October 21 2024 12:53 PM
AIDS/LifeCycle is ending after more than 30 years
October 17 2024 12:40 PM
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
October 15 2024 5:03 PM
Kentucky bans conversion therapy for youth as Gov. Andy Beshear signs 'monumental' order
September 18 2024 11:13 AM
Study finds use of puberty blockers safe and reversible, countering anti-trans accusations
September 11 2024 1:11 PM
Latinx health tips / Consejos de salud para latinos (in English & en espanol)
September 10 2024 4:29 PM